Welcome to our dedicated page for Lantern Pharma SEC filings (Ticker: LTRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lantern Pharma Inc.'s SEC filings document a clinical-stage oncology company built around AI-enabled drug development, its RADR platform and related research technologies. The filings include Form 8-K reports for financial results, Regulation FD presentations, and demonstrations of withZeta.ai, including platform capabilities, commercial architecture, rare-cancer research applications and revenue strategy disclosures.
Proxy and annual-meeting filings cover board elections, equity incentive plan matters, option repricing, independent auditor ratification and stockholder voting results. The filing record also includes exhibit-based press releases and presentations, Inline XBRL cover data, and forward-looking-statement risk language tied to Lantern Pharma's clinical programs, AI platforms, capital needs and development-stage biotechnology operations.
Lantern Pharma Inc. files its annual report describing an AI-driven oncology business that remains pre-revenue and faces substantial doubt about its ability to continue as a going concern without significant new funding. The company relies on its RADR® platform, which analyzes over 200 billion oncology-focused data points and 130,000 patient records, to select and develop drug candidates.
Lantern’s pipeline includes three clinical-stage small molecules—LP-300 for never-smoker non-small cell lung cancer, LP-184 for multiple solid tumors and CNS cancers, and LP-284 for hematologic malignancies—plus an antibody-drug conjugate program. LP-184 has received FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations in several indications, and two Phase 1b/2 INDs were cleared in 2025.
The LP-300 Phase 2 HARMONIC™ trial targets never-smoker NSCLC patients who relapsed after tyrosine kinase inhibitors, building on prior subgroup data where female patients on LP-300 plus paclitaxel/cisplatin showed median overall survival of 25.0 months versus 13.2 months on chemotherapy alone. Lantern is also preparing to commercialize its RADR® and withZeta.ai AI platforms via subscriptions and services starting in 2026.
Lantern Pharma Inc. reported narrower losses for 2025 while advancing its AI-driven oncology pipeline and platforms. Full-year net loss was about $17.1 million (or $1.57 per share), improving from roughly $20.8 million (or $1.93 per share) in 2024.
Research and development expenses fell to approximately $11.5 million, down 29%, while general and administrative costs rose modestly to about $6.5 million. Cash, cash equivalents and marketable securities were around $10.1 million as of December 31, 2025, and the company expects this to fund operations only until roughly late July to mid September 2026, so it is actively pursuing additional financing. During 2025 and early 2026 Lantern advanced multiple clinical programs, expanded its RADR® AI platform, launched the withZeta.ai co-scientist platform, and confirmed its CEO remains in place after refuting an online resignation rumor.
Lantern Pharma Inc. received an updated ownership filing showing a Bios-affiliated investment group holding a significant minority stake. Bios Capital Management, Bios Advisors GP, Cavu entities, several Bios funds and individuals Leslie W. Kreis and Aaron G.L. Fletcher may be deemed to beneficially own 960,026 common shares, representing 8.58% of the outstanding stock, all with shared voting and dispositive power and no sole voting authority. The percentages are based on 11,184,423 shares outstanding as disclosed in Lantern Pharma’s Form 10‑Q filed on November 5, 2025. This Amendment No. 5 updates prior ownership statements without describing new transactions in this excerpt.
Lantern Pharma Inc. filed a current report describing an investor and stakeholder event held on January 22, 2026. During this event, the company used a presentation to support discussions and a live demonstration of its initial artificial intelligence tools and multi-agent system that are being developed to focus on rare cancers. The same presentation is furnished as Exhibit 99.1 to the report and is not treated as formally filed financial information. This update is intended to share information under Regulation FD, giving the market equal access to the materials used at the event.
Lantern Pharma Inc. reported that director D. Jeffrey Keyser received two grants of stock options in the company. On January 9, 2026, he was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share and a second stock option to buy 28,844 shares of common stock at the same $3.49 exercise price.
The first option for 25,000 shares will vest in equal monthly installments over 24 months starting February 9, 2026. The second option for 28,844 shares will vest in equal monthly installments over 12 months starting February 9, 2026. Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan, and the filing shows these option holdings as directly owned by the reporting person.
Lantern Pharma Inc. director Maria-Luisa Maccecchini reported receiving two stock option grants. On January 9, 2026, she was awarded a stock option to buy 25,000 shares of common stock at an exercise price of $3.49 per share, with the option priced at $0.00 on the grant date. She also received a second stock option for 21,152 shares at the same $3.49 exercise price.
Both grants were made under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The 25,000-share option vests in equal monthly installments over 24 months starting February 9, 2026, while the 21,152-share option vests in equal monthly installments over 12 months beginning on the same date. Following these grants, she directly beneficially owns 25,000 and 21,152 derivative securities, respectively.
Lantern Pharma Inc. director Chandru Vijay reported receiving two new stock option grants. On January 9, 2026, he was granted stock options to buy 25,000 shares of common stock at an exercise price of $3.49 per share under the company’s Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received stock options to buy an additional 17,307 shares of common stock at an exercise price of $3.49 per share under the same plan. This second grant vests in equal monthly installments over 12 months beginning February 9, 2026. Both grants are reported as directly owned derivative securities.
Lantern Pharma director Lee Troy Schalop reported new equity awards on a Form 4. On January 9, 2026, he received two grants of stock options (rights to buy common stock) with an exercise price of $3.49 per share. One grant covers 25,000 options that vest in equal monthly installments over 24 months starting February 9, 2026. The second grant covers 18,460 options that vest in equal monthly installments over 12 months starting the same date. Both awards were reported at a transaction price of $0.00 per option, reflecting that these are option grants rather than open-market purchases or sales.
Lantern Pharma Inc. director David S. Silberstein reported receiving two grants of stock options to buy the company’s common stock. On January 9, 2026, he was awarded 25,000 stock options with an exercise price of $3.49 per share under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. These options vest in equal monthly installments over 24 months starting February 9, 2026.
On the same date, he also received an additional 17,307 stock options with the same $3.49 exercise price under the same plan. This second grant vests in equal monthly installments over 12 months beginning on February 9, 2026. Both grants are held directly by Silberstein and represent compensation in the form of equity incentives rather than an open‑market purchase.
Lantern Pharma (LTRN) reported administrative updates via Form 8-K related to third-quarter communications. The company will release financial results for the quarter ended September 30, 2025 and host a conference call and live webinar on November 13, 2025. A press release is furnished as Exhibit 99.1 and an investor presentation as Exhibit 99.2. These materials are furnished, not filed, under the Exchange Act, so they are not subject to Section 18 liability or automatically incorporated into other filings.